Advertisement

Clinical Rheumatology

, Volume 30, Issue 3, pp 429–432 | Cite as

A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept

  • Yuki Ishikawa
  • Naoichiro YukawaEmail author
  • Daisuke Kawabata
  • Koichiro Ohmura
  • Takao Fujii
  • Takashi Usui
  • Tsuneyo Mimori
Case Based Review

Abstract

In our earlier study, we had reported the case of a patient with rheumatoid arthritis (RA), who had anti-Jo-1 antibodies. This patient had received etanercept (ETN) therapy for RA, after which she had developed overt polymyositis (PM). Although various autoimmune phenomena, including lupus-like diseases, vasculitides, or psoriatic skin lesions, are associated with antitumor necrosis factor (TNF) therapy, the development of PM/dermatomyositis (DM) or antisynthetase syndrome following anti-TNF therapy is extremely rare. Here, we report a case of an RA patient with anti-PL-12 antibodies, who received ETN therapy and subsequently developed the antisynthetase syndrome. She recovered when ETN therapy was withdrawn and high-dose corticosteroid was administered. To date, there have been only five reported cases of RA patients with anti-Jo-1 antibodies who developed overt PM/DM following anti-TNF therapy and only one case of antisynthetase syndrome in an RA patient with anti-PL-7 antibodies. Our patients and the abovementioned reports strongly suggest that onset of overt PM/DM or antisynthetase syndrome in RA patients with anti-aminoacyl tRNA synthetase antibodies is associated with anti-TNF therapy.

Keywords

Adverse drug effect Anti-ARS antibodies Anti-TNF therapy Polymyositis/dermatomyositis 

Notes

Disclosures

None

References

  1. 1.
    Ishikawa Y, Yukawa N, Ohmura K et al (2010) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 29(5):563–566PubMedCrossRefGoogle Scholar
  2. 2.
    Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861PubMedCrossRefGoogle Scholar
  3. 3.
    Harald AH, Bernald Z (2006) Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis Rheum 55:982–984CrossRefGoogle Scholar
  4. 4.
    Musiał J, Undas A, Celińska-Lowenhoff M (2003) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42(12):1566–1568CrossRefGoogle Scholar
  5. 5.
    Urata Y, Wakai Y, Kowatari K (2006) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16:410–411PubMedCrossRefGoogle Scholar
  6. 6.
    Kiltz U, Fendler C, Braun J (2008) Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheum 35:2074–2075PubMedGoogle Scholar
  7. 7.
    Ishiguro T, Takayanagi N, Miyahara Y, Yanagisawa T, Sugita Y (2010) Antisynthetase (anti PL-7 antibody) syndrome presenting as a skin rash and exacerbation of interstitial pneumonia during treatment for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 48(3):240–246PubMedGoogle Scholar
  8. 8.
    Hirakata M (2000) Humoral aspects of polymyositis/dermatomyositis. Mod Rheumatol 10:199–206CrossRefGoogle Scholar
  9. 9.
    Nishikai M, Reichlin M (1980) Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 23(8):881–888PubMedCrossRefGoogle Scholar
  10. 10.
    Bunn C, Bernstein R, Mathews M (1986) Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 163(5):1281–1291PubMedCrossRefGoogle Scholar
  11. 11.
    Mathews M, Reichlin M, Hughes G, Bernstein R (1984) Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J Exp Med 160(2):420–434PubMedCrossRefGoogle Scholar
  12. 12.
    Targoff I (1990) Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 144(5):1737–1743PubMedGoogle Scholar
  13. 13.
    Hirakata M, Suwa A, Nagai S et al (1999) Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 162(4):2315–2320PubMedGoogle Scholar
  14. 14.
    Kalluri M, Sahn S, Oddis C et al (2009) Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 135(6):1550–1556PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2011

Authors and Affiliations

  • Yuki Ishikawa
    • 1
  • Naoichiro Yukawa
    • 1
    Email author
  • Daisuke Kawabata
    • 1
  • Koichiro Ohmura
    • 1
  • Takao Fujii
    • 1
  • Takashi Usui
    • 1
  • Tsuneyo Mimori
    • 1
  1. 1.Department of Rheumatology and Clinical ImmunologyKyoto University HospitalKyotoJapan

Personalised recommendations